Age-Related Macular Degeneration (ARMD) Clinical Trials

Find Age-Related Macular Degeneration (ARMD) Clinical Trials Near You

Find a DoctorCondition OverviewLatest AdvancesClinical TrialsTreatments

A Phase I, Multi-center, Multi-part Study to Investigate Safety, Tolerability, PK, PD, and Immunogenicity of RO7669330 Intravitreal Injections in Participants With GA Secondary to AMD: Part 1A: Open-label, MAD; Part 1B: Randomized PD Pilot; Part 2: Masked, Randomized, Active-comparator-controlled

Status: Recruiting
Location: See all (16) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 1
SUMMARY

The main purpose of this study is to assess the ocular and systemic safety and tolerability of RO7669330 in participants with GA secondary to AMD in at least one eye in Part 1, or both eyes in Part 2, after multiple unilateral intravitreal (IVT) doses.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 55
Healthy Volunteers: f
View:

• Adequately clear ocular media, adequate pupillary dilation, and fixation to allow acquisition of good quality fundus imaging

• GA that resides completely within the fundus autofluorescence (FAF) imaging field

• Presence of hyperautofluorescence of either banded or diffuse pattern adjacent to the GA area on FAF

• Study eye has early treatment of diabetic retinopathy study (ETDRS) best-corrected visual acuity (BCVA) score as follows:

• Part 1A: 19 to 48 letters, inclusively

• Part 1B: \> 19 letters

• Part 2: ≥ 24 letters

• Total GA lesion size must be as follows:

• Parts 1A and 1B: ≥ 1.25 square millimeter (mm\^2) and ≤ 20 mm\^2 )

• Part 2: ≥ 2.5 mm\^2 and ≤ 20 mm\^2

Locations
United States
Arizona
Associated Retina Consultants - Phoenix - DocTrials - PPDS
RECRUITING
Phoenix
Barnet Dulaney Perkins Eye Center
RECRUITING
Sun City
California
Retina-Vitreous Associates Medical Group
RECRUITING
Beverly Hills
Global Research Management
RECRUITING
Glendale
Retinal Consultants Medical Group Inc - Parkcenter Drive
RECRUITING
Sacramento
Georgia
Southeast Retina Center
RECRUITING
Augusta
Maryland
Cumberland Valley Retina Consultants PC
RECRUITING
Hagerstown
Missouri
The Retina Institute
RECRUITING
St Louis
Oregon
Retina Northwest
RECRUITING
Portland
Pennsylvania
Erie Retina Research
RECRUITING
Erie
Tennessee
Charles Retina Institute
RECRUITING
Germantown
Tennessee Retina PC
RECRUITING
Nashville
Texas
Austin Clinical Research, LLC
RECRUITING
Austin
Texas Retina Associates
RECRUITING
Dallas
Retina Consultants of Texas Westover Hills Retina Center
RECRUITING
San Antonio
Retina Consultants of Texas - (The Woodlands)
RECRUITING
The Woodlands
Contact Information
Primary
Reference Study ID Number: BP45482 https://forpatients.roche.com/
global-roche-genentech-trials@gene.com
888-662-6728 (U.S. Only)
Time Frame
Start Date: 2025-07-16
Estimated Completion Date: 2027-01-03
Participants
Target number of participants: 132
Treatments
Experimental: Part 1A: Multiple Ascending Dose (MAD)
Participants will receive multiple doses of RO7669330 as IVT injections in the study eye with additional cohorts of participants receiving higher doses of RO7669330.
Experimental: Part 1B: Syfovre and Izervay
Participants will receive either Syfovre, 15 milligrams (mg) or Izervay, 2 mg, as an IVT injection in the study eye.
Experimental: Part 2: RO7669330 vs Active Comparator (Syfovre or Izervay)
Participants will receive RO7669330 (at two dose levels) or the active comparator (either Syfovre or Izervay), as an IVT injection in the study eye.
Related Therapeutic Areas
Geographic Atrophy
Late-Onset Retinal Degeneration
Age-Related Macular Degeneration (ARMD)
Sponsors
Leads: Hoffmann-La Roche

This content was sourced from clinicaltrials.gov

Similar Clinical Trials

A Phase I, Multipart, Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7497372 Following Intravitreal Administration in Participants With Diabetic Macular Edema (Part 1 Non-Randomized, Open-Label, Multiple Ascending Dose; Part 2 Randomized, Double-Masked)

A Phase I, Multipart, Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7497372 Following Intravitreal Administration in Participants With Diabetic Macular Edema (Part 1 Non-Randomized, Open-Label, Multiple Ascending Dose; Part 2 Randomized, Double-Masked)

Enrollment Status: Recruiting
Publish Date: December 01, 2025
Intervention Type: Drug
Study Phase: Phase 1

A Phase 2, Double-masked, Randomized, Multicenter, Parallel Group, Placebo-controlled Study to Investigate the Efficacy and Safety of GAL-101, 2%, Ophthalmic Solution in Patients With Non-foveal Geographic Atrophy Secondary to Non-neovascular Age-related Macular Degeneration: eDREAM Study

A Phase 2, Double-masked, Randomized, Multicenter, Parallel Group, Placebo-controlled Study to Investigate the Efficacy and Safety of GAL-101, 2%, Ophthalmic Solution in Patients With Non-foveal Geographic Atrophy Secondary to Non-neovascular Age-related Macular Degeneration: eDREAM Study

Enrollment Status: Recruiting
Publish Date: June 25, 2025
Intervention Type: Drug
Study Phase: Phase 2

A Phase 1/2a 2-part Study Consisting of an Open-label Multiple Ascending Dose (MAD) Safety Study in Participants With Macular Edema Following Branch Retinal Vein Occlusion (BRVO), and a Dose-finding, Double-masked, Comparative Safety, and Preliminary Efficacy Study of Intravitreal (IVT) EYE201 (Tiespectus) in Participants With Either Diabetic Macular Edema (DME) or Neovascular Age-related Macular Degeneration (NVAMD)

A Phase 1/2a 2-part Study Consisting of an Open-label Multiple Ascending Dose (MAD) Safety Study in Participants With Macular Edema Following Branch Retinal Vein Occlusion (BRVO), and a Dose-finding, Double-masked, Comparative Safety, and Preliminary Efficacy Study of Intravitreal (IVT) EYE201 (Tiespectus) in Participants With Either Diabetic Macular Edema (DME) or Neovascular Age-related Macular Degeneration (NVAMD)

Enrollment Status: Recruiting
Publish Date: May 20, 2025
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
View All
For Patients
  • Our Story
  • How MediFind Works
  • Conditions A-Z
  • Doctor Directory
  • Symptoms Directory
  • Procedures Directory
  • Treatment Directory
  • Drug Directory
  • Infusion Center Finder
  • FAQ
  • Contact Us
For Providers and Practices
  • Claim Your Profile
  • Newsroom
Business Solutions
  • Provider
  • Network Solutions
Additional Resources
  • Consumer Health Data Privacy Policy
  • Privacy Policy
  • Terms of Use
  • Advertising Policy
  • Content Policy
Subscribe to our newsletter

Sign up to stay informed about MediFind and get wellness sent your way.

Close

    By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

    Bullet PinMediFind
    Follow us on
    This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
    © 2026 All Rights Reserved